Sign in

You're signed outSign in or to get full access.

TP

Traws Pharma, Inc. (ONTX)·Q2 2024 Earnings Summary

Executive Summary

  • Q2 2024 GAAP net loss was $123.1M ($4.87 per share), driven primarily by a non‑cash $117.5M acquired in‑process R&D charge related to the April merger; revenue was $0.06M and cash, cash equivalents and short‑term investments were $16.9M at quarter end .
  • Operationally, Traws advanced its antiviral pipeline: dosing began in the Phase 1 dose‑extension for tivoxavir marboxil (influenza), and the ratutrelvir (COVID‑19) Phase 1 SAD/MAD study completed; oncology strategy pivoted to ISTs for narazaciclib and continued support for rigosertib .
  • Management guided to near‑term clinical catalysts: Phase 1 topline for both antivirals in Q4 2024 and Phase 2 initiations in Q4 2024/Q1 2025; narazaciclib topline from Phase 1/2 and RP2D plus IST initiations in H2 2024 .
  • S&P Global consensus estimates for Q2 2024 revenue and EPS were unavailable due to missing CIQ mapping; comparative analysis vs Street estimates cannot be provided (S&P Global data unavailable).

What Went Well and What Went Wrong

What Went Well

  • “The last several months have been transformational for Traws Pharma… broadened our portfolio to include compounds… best‑in‑class potential for influenza… and COVID‑19,” said CEO Werner Cautreels, highlighting pipeline expansion and investor base (OrbiMed, Torrey Pines) post‑merger .
  • Tivoxavir marboxil advanced into a Phase 1 dose‑extension study; preclinical/SAD topline suggest potential for single‑dose treatment active against resistant and avian flu strains, with Phase 2 initiation targeted Q4 2024/Q1 2025 .
  • Ratutrelvir completed Phase 1 SAD/MAD in Australia with potential to avoid CYP‑inhibitor co‑administration; Phase 2 initiation targeted Q4 2024/Q1 2025 .

What Went Wrong

  • Q2 2024 reported a large GAAP net loss due to the $117.5M non‑cash IPR&D charge associated with the transaction, obscuring underlying operating trends .
  • R&D expense rose to $4.0M in Q2 (vs $2.5M in Q2 2023) reflecting COVID‑19 and influenza studies and completion of narazaciclib Phase 1/2 dose escalation; G&A remained elevated due to stock‑based comp and restructuring tied to the merger .
  • Cash declined to $16.9M from $20.8M at year‑end; management indicated cash supports planned operations through year‑end 2024, underscoring near‑term financing sensitivity .

Financial Results

Metric ($USD)Q2 2023Q1 2024Q2 2024
Revenue$57,000 $56,000 $57,000
R&D Expense$2,456,000 $1,912,000 $3,964,000
G&A Expense$2,211,000 $3,356,000 $1,977,000
Total Operating Expenses$4,667,000 $5,268,000 $123,405,000
Net Loss$(4,250,000) $(4,983,000) $(123,143,000)
Diluted EPS$(0.20) $(0.24) $(4.87)

KPIs and Balance Sheet

KPI ($USD)Dec 31, 2023Mar 31, 2024Jun 30, 2024
Cash, Cash Equivalents & Short‑Term Investments$20,821,000 $16,390,000 $16,886,000
Accounts Payable$5,619,000 $6,568,000 $6,174,000
Accrued Expenses & Other Current Liabilities$3,375,000 $2,628,000 $3,509,000
Deferred Revenue (Current)$226,000 $226,000 $227,000
Series C Redeemable Convertible Preferred (shares/outstanding; carrying value)— — 12,472 shares; $111,619,000

Notes:

  • Q2 2024 includes $117.5M acquired IPR&D within operating expenses, driving the sharp YoY increase .
  • Weighted average shares: 20.98M (Q2 2023), 21.04M (Q1 2024), 25.31M (Q2 2024) .

Guidance Changes

Metric/ProgramPeriodPrevious GuidanceCurrent GuidanceChange
Tivoxavir marboxil Phase 2 initiationH2 2024H2 2024 initiation Q4 2024/Q1 2025 initiation Slightly refined/pushed timing
Tivoxavir marboxil Phase 1 dose‑extension toplineQ4 2024Not specified priorQ4 2024 topline New specific date
Ratutrelvir Phase 2 initiationH2 2024H2 2024 initiation Q4 2024/Q1 2025 initiation Slightly refined/pushed timing
Ratutrelvir Phase 1 SAD/MAD toplineQ4 2024H2 2024 topline expected Q4 2024 topline Narrowed window
Narazaciclib RP2D + ISTsH2 2024Safety/PK readout H1 2024; registrational prep updates upcoming RP2D announcement and IST initiations in H2 2024 Delayed to H2 2024
Cash runwayFY2024Funding into Q4 2024 Adequate to support planned operations through year‑end 2024 Maintained/clarified

Earnings Call Themes & Trends

TopicPrevious Mentions (Q‑2 and Q‑1)Current Period (Q2 2024)Trend
Antiviral pipeline executionQ1: Initiated COVID‑19 SAD/MAD; planning Phase 2 for both antivirals in H2 2024 . Q3 2023: No antiviral programs pre‑merger (Onconova oncology focus) .Tivoxavir Phase 1 dose‑extension dosing underway; ratutrelvir SAD/MAD completed; Phase 2 for both targeted Q4 2024/Q1 2025 .Acceleration with refined timelines post‑merger
Oncology strategy pivotQ3 2023: Narazaciclib progressing; acceptable safety; registrational prep for endometrial cancer . Q1 2024: Last dose escalation cohort enrolled; strategy definition underway .ISTs planned for multiple myeloma and breast cancer; narazaciclib topline from Phase 1/2 to be released; RP2D to be announced H2 2024; continued rigosertib support .Pivot from endometrial toward investigator‑led studies in broader indications
Capital and runwayQ3 2023: Cash $25.2M; runway into Q3 2024 . Q1 2024: Cash $16.4M; $14M private placement; runway into Q4 2024 .Cash $16.9M; runway through year‑end 2024; expanded investor base via OrbiMed/Torrey Pines .Stable but relatively short runway; investor base strengthened
Merger/strategic positioningQ1 2024: Completed acquisition of Trawsfynydd and financing .Post‑merger portfolio broadened; “transformational” period emphasized by CEO; corporate update call .Integration benefits highlighted

Management Commentary

  • CEO Werner Cautreels: “Completion of the merger… broaden[ed] our portfolio to include compounds… best‑in‑class potential for influenza… and COVID‑19… ISTs are enhancing our multi‑kinase inhibitors for cancer, narazaciclib and rigosertib” .
  • CEO on antivirals: Tivoxavir “has the potential to achieve our target product profile as a single dose treatment… active against pandemic‑potential viruses as well as oseltamivir and baloxavir resistant viruses,” and ratutrelvir “has the potential to be effective without… a CYP‑inhibitor… active against virus strains… resistant to other approved agents such as nirmatrelvir” .
  • CFO Mark Guerin (call): “The net loss… of $123.1 million, or $4.87… reflects a noncash charge of $117.5 million related to in‑process R&D from Onconova’s April 2024 acquisition of Trawsfynydd. Traws… closed… with cash… $16.9 million” .

Q&A Highlights

  • Influenza Phase 1 dose‑extension: Approximately 24–26 healthy volunteers in a placebo‑controlled study; Phase 2 design/timing to be finalized after analyzing Phase 1 data .
  • Oncology focus: Endometrial cancer not current priority; high investigator interest driving narazaciclib ISTs in multiple myeloma and breast cancer .
  • Financials clarification: Management reiterated the non‑cash nature of the IPR&D charge and runway through year‑end .

Estimates Context

  • S&P Global consensus estimates for Q2 2024 revenue and EPS were unavailable due to missing CIQ mapping; as a result, we cannot quantify beats/misses vs Street (S&P Global data unavailable).
  • Given the lack of financial guidance and minimal reported revenue, Street models are likely to focus on clinical timelines and cash runway; the refined timing for Phase 2 initiations and the H2 2024 narazaciclib milestones may prompt timing adjustments in R&D spending and milestone expectations .

Key Takeaways for Investors

  • The headline GAAP loss was dominated by a one‑time, non‑cash IPR&D charge; underlying operating loss excluding this item remained in line with historical scale for a clinical‑stage biotech .
  • Near‑term binary catalysts are concentrated in Q4 2024/Q1 2025 for both antivirals (Phase 1 topline and Phase 2 starts); monitoring data quality and regulatory interactions will be key to sentiment .
  • Oncology strategy is shifting toward investigator‑sponsored breadth (multiple myeloma, breast), with RP2D determination for narazaciclib in H2 2024 offering a potential inflection point .
  • Cash of $16.9M and runway through year‑end 2024 suggests financing optionality will be an overhang without partnership non‑dilutive sources; watch for BD updates and grant/agency engagement .
  • Absence of Street consensus comparables limits near‑term “beat/miss” trading setups; focus should be on clinical execution timelines and any safety/PK signals emerging in Q4 .
  • Post‑merger investor base (OrbiMed, Torrey Pines) and portfolio expansion improve strategic positioning for future capital raises contingent on data .
  • Tactical stance: trade around catalyst dates (Phase 1 topline) while managing dilution risk; medium‑term thesis hinges on differentiation claims (single‑dose flu; CYP‑independent COVID) translating into robust Phase 2 efficacy .